We prospectively evaluated whether an effective 12-month uric acid-lowering therapy (ULT)
with the available xanthine oxidase (XO) inhibitors allopurinol and febuxostat in patients with …

Objective To investigate whether serum urate levels, number of gout flares, and tophi burden
are related to death from cardiovascular (CV) causes after treatment with febuxostat or …

Objective. To determine longterm urate-lowering efficacy and clinical benefits and safety of
therapy with febuxostat or allopurinol in subjects with gout. Methods. Subjects (n= 1086) in …

Febuxostat is a new non-purine xanthine oxidase inhibitor that is more potent than
allopurinol 300 mg daily. In two Phase III trials, significantly more febuxostat-treated gout …

Objectives. To determine if urate-lowering treatment (ULT) in gout can reduce
cardiovascular (CV) outcomes. Methods. Randomized trials were searched for treatment …

Objective Renal impairment is a risk factor for gout and a barrier to optimal gout
management. We undertook this exploratory study to obtain data that have been heretofore …

Objective. Hyperuricemia of gout can arise due to either overproduction or underexcretion of
uric acid. Not all available urate-lowering therapies are equally effective and safe for use in …

Aim Febuxostat, a novel non‐purine selective inhibitor of xanthine oxidase, has been
identified as a potential alternative to allopurinol in patients with hyperuricemia. The purpose …

Background Patients with gout have arterial dysfunction and systemic inflammation, even
during intercritical episodes, which may be markers of future adverse cardiovascular …

Background: The association between hyperuricemia, gout, and impaired renal function has
long been recognized. Recent data provide evidence for the causal relationship between …